- $662.30m
- $251.53m
Brief: Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Domino's Pizza, Honeywell, Walmart
Brief: Olema Oncology Announces FDA Clearance Of Investigational New Drug Application For OP-3136
Brief: Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Olema Oncology Announces New Clinical Trial Collaboration And Supply Agreement With Novartis In Frontline Metastatic Breast Cancer As Well As $250 Million Equity Private Placement
U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, Walmart
Olema Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Olema Oncology Q3 Net Income USD -34.555 Million
Olema Pharmaceuticals Inc expected to post a loss of 58 cents a share - Earnings Preview
Olema Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Olema Oncology Q2 Net Income USD -30.382 Million
Olema Pharmaceuticals Inc expected to post a loss of 55 cents a share - Earnings Preview
Brief: Olema Pharmaceuticals Got Into First Amendment To Loan & Security Agreement
U.S. RESEARCH ROUNDUP-Deere & Co, Under Armour, Walmart
U.S. RESEARCH ROUNDUP-AN2 Therapeutics, Ecolab, RPM International
Brief: Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
Brief: Olema Oncology Q1 Net Income USD -30.97 Million
Brief: Olema Oncology Announces New Clinical Data For Palazestrant In Combination With Ribociclib To Be Presented At The 2024 Esmo Breast Cancer Annual Congress
Olema Pharmaceuticals Inc expected to post a loss of 55 cents a share - Earnings Preview